Metabolic Control and Patient Well-being in Phenylketonuria: do Guidelines Make a Difference?

Phenylketonurias Clinical Trial

— PKU_Guide  

Official title:

Metabolic Control and Patient Well-being in Phenylketonuria: do Guidelines Make a Difference?

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05128149
• Other study ID #: PKU_Guide
• Status: Recruiting
• Start date: November 15, 2021
• Est. completion date: December 31, 2024

Study information

• Verified date: December 2023
• Source: University Children's Hospital, Zurich
• Contact: Martina Huemer, Prof
• Phone: +41 44 2660
• Email: martina.huemer[@]kispi.uzh.ch
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Treatment of PKU implies for most patients that with strict adherence to dietary treatment they can achieve excellent neurocognitive outcome. Dietary treatment, though, is hard to comply to every day and with every single meal. Unsurprisingly, health-related quality of life (HrQol) is negatively affected if patients have to follow a dietary regime of this kind. Adherence to treatment in PKU is very variable. Factors of significant impact on adherence to treatment and well-being in chronic disease such as self-efficacy or parenting stress have not yet been widely investigated in PKU patients.

The ideal treatment prescription (and guideline) recommends as much as necessary and as little as possible, based on the best evidence available. Patients should neither be deprived of treatment options nor be exposed to overtreatment.

This study investigates adherence, metabolic control, HrQol in PKU patients treated by centres which follow different guidelines

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 31, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 10 Years and older

Eligibility

Inclusion Criteria:- Patients with PKU from age 10 years requiring dietary and / or pharmacological treatment according to locally applied guidelines

• Parents of patients with PKU aged 10 to 18 years requiring dietary and / or pharmacological treatment according to locally applied guidelines

• Ability and willingness to answer the questionnaires and follow the study procedures

• Informed consent as documented by signature

Exclusion criteria for patients and parents :

• Inability to follow the procedures of the study, e.g. due to language problems or severely reduced health status

• Pregnant patients or patients who have disclosed to their physician that they are planning a pregnancy in the near future

• Hyperphenylalaninaemia or mild forms of PKU or other inborn errors associated with elevated Phe but not requiring dietary and / or pharmacological treatment according to locally applied guidelines

• No inform

Related Conditions & MeSH terms

• Phenylketonurias

Intervention

Other:
• no intervention
no intervention

Locations

Country	Name	City	State
Switzerland	University Childrens Hospital Zürich	Zürich

Sponsors (4)

Lead Sponsor	Collaborator
University Children's Hospital, Zurich	Insel Gruppe AG, University Hospital Bern, UChildrenVienna, University Children's Hospital Basel

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phe values	biochemical marker for PKU	report on measurements from past 24 months
Secondary	Health-related quality of life	PKU-QoL© Questionnaire	one hour
Secondary	Self-efficacy	10 items Self-efficacy scale (Schwarzer& Jerusalem)	one hour
Secondary	Burden on family (patients from 10-18 years)	Revised Impact on Family Scale	one hour